Disorders of phosphate metabolism - Pathomechanisms and management of hypophosphataemic disorders

Bailliere's Best Practice and Research in Clinical Endocrinology and Metabolism

Volumn 17, Issue 4, 2003, Pages 547-558

  Ritz, Eberhard ^a   Haxsen, Volker ^a   Zeier, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

ADHR; FGF 23; Nephrocalcinosis; Octreotide; Phosphate; Phosphatonin; Tumour induced osteomalacia; XLH

Indexed keywords

CALCITRIOL; CALCIUM; CALCIUM CARBONATE; DISODIUM HYDROGEN PHOSPHATE; FIBROBLAST GROWTH FACTOR; OCTREOTIDE; PHOSPHATE; PROTEINASE; SODIUM DIHYDROGEN PHOSPHATE; SOMATOSTATIN DERIVATIVE; VITAMIN D; VITAMIN D DERIVATIVE;

ALKALOSIS; AUTOSOMAL DOMINANT DISORDER; BONE DISEASE; CANCER SURGERY; CARDIOMYOPATHY; DIARRHEA; DIETARY INTAKE; DIFFERENTIAL DIAGNOSIS; DRUG DOSE REGIMEN; EMERGENCY; GASTROINTESTINAL INTOLERANCE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPOPHOSPHATEMIA; KIDNEY CALCIFICATION; MALIGNANT NEOPLASTIC DISEASE; MYOPATHY; NONHUMAN; OSTEOMALACIA; PATHOPHYSIOLOGY; PHOSPHATE METABOLISM; PHYSIOLOGY; REVIEW; RICKETS; SECONDARY HYPERPARATHYROIDISM; SEPTICEMIA; X CHROMOSOME LINKED DISORDER; AUTOSOMAL DOMINANT INHERITANCE; CYTOKINE PRODUCTION; PATHOGENESIS; PHOSPHATE DEFICIENCY; PHOSPHATURIA; TUMOR; VITAMIN D RESISTANT RICKETS;

EID: 0345603096     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-690X(03)00055-1     Document Type: Review

References (40)

1. Ritz E. Acute hypophosphataemia. Kidney International 1982; 22: 84-94.
2. Levine BS & Kleeman CR. Hypophosphataemia and hyperphosphatemia: Clinical and pathophysiological aspects. In Narins RE (ed.) Maxwell and Kleeman's Clinical Disorders of Fluid and Electrolyte Metabolism, 5th edn., New York: McGraw-Gill, 1994, pp 1045-1097.
3. Tenenhouse HS & Murer H. Disorders of renal tubular phosphate transport. Journal of the American Society of Nephrology 2003; 14: 240-247.
4. Lloyd SE, Pearce SH, Fisher SE et al. A common molecular basis for three inherited kidney stone diseases. Nature 1996; 379: 445-449.
5. McCance R. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age 15 years. Quarterly Journal of Medicine 1947; 16: 33-46.
6. Yeung SJ, McCutheon IE, Schultz P et al. Use of long-term intravenous phosphate infusion in the palliative treatment of tumour-induced osteomalacia. Journal of Clinical Endocrinology and Metabolism 2000; 85: 549-555.
7. Case records of the Massachusetts General Hospital, weekly clinicopathological exercises. Case 29-2001. A 14-year-old with abnormal bones and a sacral mass. New England Journal of Medicine 2001; 345: 903-908.
8. Catalano PJ, Brandwein M, Shah DK et al. Sinonasal hemangiopericytomas: A clinicopathologic and immunohistochemical study of seven cases. Head and Neck 1996; 18: 42-53.
9. Ben-Baruch D, Ziv Y, Sandbank J et al. Oncogenic osteomalacia induced by schwannoma in a patient with neurofibromatosis. European Journal of Surgical Oncology 1994; 20: 57-61.
10. Cai Q, Hodgson SF, Kao PC et al. Brief report: Inhibition of renal phosphate transport by a tumour product in a patient with oncogenic osteomalacia. New England Journal of Medicine 1994; 330: 1645-1649.
11. Harvey JN, Gray C & Belchetz PE. Oncogenous osteomalacia and malignancy. Clinical Endocrinology (Oxford) 1992; 37: 379-382.
12. Rico H, Fernandez-Miranda E. Sanz J et al. Oncogenous osteomalacia: A new case secondary to a malignant tumour. Bone 1986; 7: 325-329.
13. Sparagana M. Tumour-induced osteomalacia: Long-term follow-up of two patients cured by removal of their tumours. Journal of Surgical Oncology 1987; 36: 198-205.
14. Reese DM & Rosen PJ. Oncogenic osteomalacia associated with prostate cancer. Journal of Urology 1997; 158: 887.
15. Nuovo MA, Dorfman HD, Sun CC et al. Tumour-induced osteomalacia and rickets. American Journal of Surgical Pathology 1989; 13: 588-599.
16. Crouzet J, Mimoune H, Beraneck L et al. Hypophosphataemic osteomalacia with plantar neurilemoma. A review of the literature (100 cases). Revue de Rhumatisme, English Edition 1995; 62: 463-466.
17. Kumar R. Phosphatonin - A new phosphaturetic hormone? (lessons from tumour-induced osteomalacia and X-linked hypophosphataemia). Nephrology, Dialysis, Transplantation 1997; 12: 11-13.
18. Schiavi SC & Moe OW. Phosphatonins: A new class of phosphate-regulating proteins. Current Opinion in Nephrology and Hypertension 2002; 11: 423-430.
19. Jonsson KB, Mannstadt M, Miyauchi A et al. Extracts from tumours causing oncogenic osteomalacia inhibit phosphate uptake in opossum kidney cells. Journal of Endocrinology 2001; 169: 613-620.
20. Tenenhouse HS & Sabbagh Y. Novel phosphate-regulating genes in the pathogenesis of renal phosphate wasting disorders. Pflugers Archiv 2002; 444: 317-326.
21. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumour-induced osteomalacia. Proceedings of the National Academy of Sciences of the USA 2001; 98: 6500-6505.
22. Shimada T, Muto T, Hasegawa H et al. FGF-23 is a novel regulator of mineral homeostasis with unique properties controlling vitamin D metabolism and phosphate reabsorption. Journal of Bone and Mineral Research 2002; 17: S425. abstract
23. Shimada T, Muto T, Urakawa I et al. Mutant FGF-23 responsible for autosomal dominant hypophosphataemic rickets is resistant to proteolytic cleavage and causes hypophosphataemia in vivo. Endocrinology 2002; 143: 3179-3182.
24. Rowe PS, De Zoysa PA, Dong R et al. MEPE, a new gene expressed in bone marrow and tumours causing osteomalacia. Genomics 2000; 67: 54-68.
25. Johnsson KB, Zahradnik R, Larsson T et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphataemia. New England Journal of Medicine 2003; 348: 1656-1663.
26. Seufert J, Ebert K, Muller J et al. Octreotide therapy for tumour-induced osteomalacia. New England Journal of Medicine 2001; 345: 1883-1888.
27. Meyer RA Jr, Tenenhouse HS, Meyer MH et al. The renal phosphate transport defect in normal mice parabiosed to X-linked hypophosphataemic mice persists after parathyroidectomy. Journal of Bone and Mineral Research 1989; 4(4): 523-532.
28. Meyer Jr. RA, Meyer MH Gray RW. Parabiosis suggests a humoral factor is involved in X-linked hypophosphataemia in mice. Journal of Bone and Mineral Research 1989; 4: 493-500.
29. Nesbitt T, Coffman TM, Griffiths R et al. Crosstransplantation of kidneys in normal and Hyp mice. Evidence that the Hyp mouse phenotype is unrelated to an intrinsic renal defect. Journal of Clinical Investigation 1992; 89: 1453-1459.
30. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphataemic rickets. The HYP Corsortium. Nature Genetics 1995; 11: 130-136.
31. Westbroek I, De Rooij KE, & Nijweide PJ. Osteocyte-specific monoclonal antibody MAb OB7.3 is directed against Phex protein. Journal of Bone and Mineral Research 2002; 17: 845-853.
32. White KE, Carn G, Lorenz-Depiereux B et al. Autosomal-dominant hypophosphataemic rickets (ADHR) mutations stabilize FGF-23. Kidney International 2001; 60: 2079-2086.
33. Shih NR, Jo OD & Yanagawa N. Effects of PHEX antisense in human osteoblasts cells. Journal of the American Society of Nephrology 2002; 13: 394-399.
34. Boileau G, Tenenhouse HS, Desgroseillers L et al. Characterization of PHEX endopeptidase catalytic activity: Identification of parathyroid-hormone-related peptide 107-139 as a substrate and osteocalcin, PPi and phosphate as inhibitors. Biochemical Journal 2001; 355: 707-713.
35. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. The ADHR Consortium. Nature Genetics 2000;26:345-348.
36. Tieder M, Modai D, Samuel R et al. Hereditary hypophosphataemic rickets with hypercalciuria. New England Journal of Medicine 1985; 312: 611-617.
37. Jones A, Tzenova J, Frappier D et al. Hereditary hypophosphataemic rickets with hypercalciuria is not caused by mutations in the Na/Pi cotransporter NPT2 gene. Journal of the American Society of Nephrology 2001; 12: 507-514.
38. Prié D, Huart V, Bakouch N et al. Nephrolithiasis and osteoporosis associated with hypophosphataemia caused by mutations in the type 2a sodium-phosphate cotransporter. New England Journal of Medicine 2002; 347: 983-991.
39. Silve C & Beck L. Is FGF23 the long sought after phosphaturic factor phosphatonin? Nephrology, Dialysis, Transplantation 2002; 17: 958-961.
40. Carpenter TO. Oncogenic osteomalacia - A complex dance of factors. New England Journal of Medicine 2003; 348: 1705-1708.